Differentiating between progressive supranuclear palsy and corticobasal degeneration by brain perfusion spet

Nuclear Medicine Communications

Volumn 22, Issue 7, 2001, Pages 767-772

  Zhang, L ^a   Murata, Y ^a   Ishida, R ^a   Saitoh, Y ^a   Mizusawa, H ^a   Shibuya, H ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

99mTc ethyl cysteinate dimer; Corticobasal degeneration; Progressive supranuclear palsy; Single photon emission computed tomography

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN PERFUSION; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; MALE; PARIETAL LOBE; PROGRESSIVE SUPRANUCLEAR PALSY; RADIODIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL CORTEX; THALAMUS;

AGED; AGED, 80 AND OVER; BASAL GANGLIA; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; CYSTEINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SUPRANUCLEAR PALSY, PROGRESSIVE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034952648     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200107000-00007     Document Type: Review

References (18)

1. Giménez-Roldán S, Mateo D, Benito C, Grandas F, Pérez-Gilabert Y. Progressive supranuclear palsy and corticobasal ganglionic degeneration: differentiation by clinical features and neuroimaging techniques. J Neural Transm Suppl 1994; 42: 79-90.
2. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112: 1171-1192.
3. Blin J, Baron JC, Dubois B et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990; 47: 747-752.
4. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988; 24: 399-406.
5. Eidelberg D, Dhawan V, Moeller JR et al. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1992; 54: 856-862.
6. Sawle GV, Brooks DJ, Marsden CD, Frackowiak RS. Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 1991; 114: 541-556.
7. Johnson KA, Sperling RA, Leonard Holman B, Steven Nagel J, Growdon JH. Cerebral perfusion in progressive supranuclear palsy. J Nucl Med 1992; 33: 704-709.
8. Soliveri P, Monza D, Paridi D et al. Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. Neurology 1999; 53: 502-507.
9. Matsuda H, Tsuji S, Shuke N, Sumiya H, Tonami N, Hisada K. A quantitative approach to technetium-99m ethyl cysteinate dimer: a comparison with technetium-99m hexamethylpropylene amine oxime. Eur J Nucl Med 1995; 22: 633-637.
10. 2 receptor SPECT analysis. Eur Neurol 1995; 35: 50-54.
11. Hauser RA, Murtaugh FR, Akhter K, Gold M, Olanow CW. Magnetic resonance imaging of corticobasal degeneration. J Neuroimaging 1996; 6: 223-226.
12. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994; 117: 1183-1196.
13. Tokumaru A, O’uchi T, Kuru Y, Maki T, Murayama S, Horichi Y. Corticobasal degeneration: MR with histopathologic comparison. Am J Neuroradiol 1996; 17: 1849-1852.
14. Okuda B, Tachibana H, Kawabata K, Kakeda M, Sugita M. Cerebral blood flow correlates of higher brain dysfunctions in corticobasal degeneration. J Geriatr Psychiatry Neurol 1999; 12: 189-193.
15. Markus HS, Lees AJ, Lennox G, Marsden CD, Costa DC. Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT: comparison with Parkinson’s disease and normal controls. Mov Disord 1995; 10: 179-187.
16. Johannes H, Michael C, Stephan V et al. Loss of dopamine-D2 receptor binding sites in parkinsonian plus syndromes. J Nucl Med 1998; 39: 954-960.
17. Buck A, Westera G, Sutter M, Albani C, Kung HF, Vonschulthess GK. Iodine-123-IBF SPET evaluation of extrapyramidal diseases. J Nucl Med 1995; 36: 1196-1200.
18. Yokota T, Saito Y, Shimizu Y. Increased corticomotoneuronal excitability after peripheral nerve stimulation in dopa-nonresponsive hemiparkinsonism. J Neurol Sci 1995; 129: 34-39.